512 related articles for article (PubMed ID: 28865972)
1. High-Dose Melphalan and Stem Cell Transplantation in Patients on Dialysis Due to Immunoglobulin Light-Chain Amyloidosis and Monoclonal Immunoglobulin Deposition Disease.
Batalini F; Econimo L; Quillen K; Sloan JM; Sarosiek S; Brauneis D; Havasi A; Stern L; Dember LM; Sanchorawala V
Biol Blood Marrow Transplant; 2018 Jan; 24(1):127-132. PubMed ID: 28865972
[TBL] [Abstract][Full Text] [Related]
2. Safety and Efficacy of Propylene Glycol-Free Melphalan in Patients with AL Amyloidosis Undergoing Autologous Stem Cell Transplantation: Results of a Phase II Study.
Sarosiek S; Lee MH; Doros G; Edwards CV; Quillen K; Brauneis D; Shelton AC; Sanchorawala V; Sloan JM
Transplant Cell Ther; 2023 Nov; 29(11):695.e1-695.e7. PubMed ID: 37607644
[TBL] [Abstract][Full Text] [Related]
3. An overview of the use of high-dose melphalan with autologous stem cell transplantation for the treatment of AL amyloidosis.
Sanchorawala V; Wright DG; Seldin DC; Dember LM; Finn K; Falk RH; Berk J; Quillen K; Skinner M
Bone Marrow Transplant; 2001 Oct; 28(7):637-42. PubMed ID: 11704785
[TBL] [Abstract][Full Text] [Related]
4. Modified High-Dose Melphalan and Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Nguyen VP; Landau H; Quillen K; Brauneis D; Shelton AC; Mendelson L; Rahman H; Sloan JM; Sarosiek S; Sanchorawala V
Biol Blood Marrow Transplant; 2018 Sep; 24(9):1823-1827. PubMed ID: 29933072
[TBL] [Abstract][Full Text] [Related]
5. Pre-transplantation novel agent induction predicts progression-free survival for patients with immunoglobulin light-chain amyloidosis undergoing high-dose melphalan and autologous stem cell transplantation.
Cowan AJ; Klippel ZK; Stevenson PA; Hyun TS; Tuazon S; Becker PS; Green DJ; Holmberg LA; Coffey DG; Gopal AK; Libby EN
Amyloid; 2016 Dec; 23(4):254-259. PubMed ID: 27879147
[TBL] [Abstract][Full Text] [Related]
6. High-dose melphalan and auto-SCT in patients with monoclonal Ig deposition disease.
Hassoun H; Flombaum C; D'Agati VD; Rafferty BT; Cohen A; Klimek VM; Boruchov A; Kewalramani T; Reich L; Nimer SD; Comenzo RL
Bone Marrow Transplant; 2008 Sep; 42(6):405-12. PubMed ID: 18574442
[TBL] [Abstract][Full Text] [Related]
7. Effect of severe hypoalbuminemia on toxicity of high-dose melphalan and autologous stem cell transplantation in patients with AL amyloidosis.
Lee SY; Meehan RS; Seldin DC; Sloan JM; Quillen K; Shelton A; Brauneis D; Sanchorawala V
Bone Marrow Transplant; 2016 Oct; 51(10):1318-1322. PubMed ID: 27183092
[TBL] [Abstract][Full Text] [Related]
8. High-dose intravenous melphalan with autologous stem cell transplantation in AL amyloidosis-associated end-stage renal disease.
Casserly LF; Fadia A; Sanchorawala V; Seldin DC; Wright DG; Skinner M; Dember LM
Kidney Int; 2003 Mar; 63(3):1051-7. PubMed ID: 12631087
[TBL] [Abstract][Full Text] [Related]
9. Short and long-term outcome of treatment with high-dose melphalan and stem cell transplantation for multiple myeloma-associated AL amyloidosis.
Girnius S; Seldin DC; Skinner M; Finn KT; Quillen K; Doros G; Sanchorawala V
Ann Hematol; 2010 Jun; 89(6):579-84. PubMed ID: 20012043
[TBL] [Abstract][Full Text] [Related]
10. Induction Therapy with Bortezomib Followed by Bortezomib-High Dose Melphalan and Stem Cell Transplantation for Light Chain Amyloidosis: Results of a Prospective Clinical Trial.
Sanchorawala V; Brauneis D; Shelton AC; Lo S; Sun F; Sloan JM; Quillen K; Seldin DC
Biol Blood Marrow Transplant; 2015 Aug; 21(8):1445-51. PubMed ID: 25858810
[TBL] [Abstract][Full Text] [Related]
11. Predictors and outcomes of acute kidney injury during autologous stem cell transplantation in AL amyloidosis.
Nader R; Zhen A; Angel-Korman A; Pavlovich SS; Pogrebinsky A; Doros G; Menn-Josephy H; Stern L; Sanchorawala V; Havasi A
Nephrol Dial Transplant; 2022 Jun; 37(7):1281-1288. PubMed ID: 34043009
[TBL] [Abstract][Full Text] [Related]
12. Modified High-Dose versus High-Dose Melphalan Conditioning in Older Patients Undergoing Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis.
Hassan H; Verma K; Ferri G; Brauneis D; Quillen K; Sloan JM; Sanchorawala V; Edwards CV
Transplant Cell Ther; 2022 Nov; 28(11):761.e1-761.e7. PubMed ID: 35970300
[TBL] [Abstract][Full Text] [Related]
13. Induction Therapy with Bortezomib and Dexamethasone and Conditioning with High-Dose Melphalan and Bortezomib Followed by Autologous Stem Cell Transplantation for Immunoglobulin Light Chain Amyloidosis: Long-Term Follow-Up Analysis.
Gupta VK; Brauneis D; Shelton AC; Quillen K; Sarosiek S; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2019 May; 25(5):e169-e173. PubMed ID: 30639823
[TBL] [Abstract][Full Text] [Related]
14. The Effect of Bone Marrow Plasma Cell Burden on Survival in Patients with Light Chain Amyloidosis Undergoing High-Dose Melphalan and Autologous Stem Cell Transplantation.
Dittus C; Uwumugambi N; Sun F; Sloan JM; Sanchorawala V
Biol Blood Marrow Transplant; 2016 Sep; 22(9):1729-1732. PubMed ID: 27296954
[TBL] [Abstract][Full Text] [Related]
15. Microbiologically documented infections in patients undergoing high-dose melphalan and autologous stem cell transplantation for the treatment of light chain amyloidosis.
Taimur S; Nader C; Lloyd-Travaglini C; Seldin DC; Sanchorawala V
Transpl Infect Dis; 2013 Apr; 15(2):187-94. PubMed ID: 23279695
[TBL] [Abstract][Full Text] [Related]
16. A second course of high-dose melphalan and auto-SCT for the treatment of relapsed AL amyloidosis.
Quillen K; Seldin DC; Finn KT; Sanchorawala V
Bone Marrow Transplant; 2011 Jul; 46(7):976-80. PubMed ID: 20956955
[TBL] [Abstract][Full Text] [Related]
17. Outcome of AL amyloidosis after high-dose melphalan and autologous stem cell transplantation: long-term results in a series of 421 patients.
Cibeira MT; Sanchorawala V; Seldin DC; Quillen K; Berk JL; Dember LM; Segal A; Ruberg F; Meier-Ewert H; Andrea NT; Sloan JM; Finn KT; Doros G; Blade J; Skinner M
Blood; 2011 Oct; 118(16):4346-52. PubMed ID: 21828140
[TBL] [Abstract][Full Text] [Related]
18. Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study.
Gustine JN; Staron A; Szalat RE; Mendelson LM; Joshi T; Ruberg FL; Siddiqi O; Gopal DM; Edwards CV; Havasi A; Kaku M; Lau KHV; Berk JL; Sloan JM; Sanchorawala V
Am J Hematol; 2022 Sep; 97(9):1189-1199. PubMed ID: 35731907
[TBL] [Abstract][Full Text] [Related]
19. Tandem cycles of high-dose melphalan and autologous stem cell transplantation increases the response rate in AL amyloidosis.
Sanchorawala V; Wright DG; Quillen K; Finn KT; Dember LM; Berk JL; Doros G; Fisher C; Skinner M; Seldin DC
Bone Marrow Transplant; 2007 Sep; 40(6):557-62. PubMed ID: 17589534
[TBL] [Abstract][Full Text] [Related]
20. Induction therapy with bortezomib and dexamethasone followed by autologous stem cell transplantation versus autologous stem cell transplantation alone in the treatment of renal AL amyloidosis: a randomized controlled trial.
Huang X; Wang Q; Chen W; Zeng C; Chen Z; Gong D; Zhang H; Liu Z
BMC Med; 2014 Jan; 12():2. PubMed ID: 24386911
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
